Latest Surgical oncology Stories
The number of signatures continues to grow, despite a recent decision by the FDA not to ban power morcellators. New York, New York (PRWEB) December 27, 2014
The publication of this latest power morcellator study follows warnings from U.S.
First study to show that the genomic signature of prostate cancer can predict rapid development of metastatic disease in men who were managed conservatively after surgery SAN DIEGO, Dec.
Power morcellators first came to market decades ago, under the FDA’s 510(k) clearance program, which in most cases does not require controlled human testing. New
Growing body of clinical evidence shows greater penetration, targeted delivery, efficiency and cost savings with the SIS WESTMINSTER, Colo., Dec.
- Late-Breaking Data From Pilot Study on New Electromagnetic Wave Device For Tissue Targeting During Breast Conservation Surgery at San Antonio Breast Cancer Symposium - SAN ANTONIO,
Research Shows Promise in Reducing Complications of Gastrointestinal Surgery COLUMBIA, Md., Dec. 9, 2014 /PRNewswire/ -- ACell, Inc.
AMSTERDAM, December 9, 2014 /PRNewswire/ -- ~ Data confirms the potential of ATIR(TM) in partially matched hematopoietic stem cell transplants ~ Kiadis Pharma
The doctor who is spearheading a petition to ban power morcellators says the FDA’s most recent warning is not enough to protect hysterectomy and fibroid removal patients from the risk of spreading
- A bereavement by loss of parents or children; the state of being orbate; orbation.